sulfinpyrazone and Cytokine Release Syndrome
sulfinpyrazone has been researched along with Cytokine Release Syndrome in 1 studies
Sulfinpyrazone: A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties.
Cytokine Release Syndrome: A severe immune reaction characterized by excessive release of CYTOKINES. Symptoms include DYSPNEA; FEVER; HEADACHE; HYPOTENSION; NAUSEA; RASH; TACHYCARDIA; HYPOXIA; HYPERFERRITINEMIA, and MULTIPLE ORGAN FAILURE. It is associated with viral infections, SEPSIS; AUTOIMMUNE DISEASES and a variety of factors used in IMMUNOTHERAPY.
Research
Studies (1)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Abo Elmaaty, A | 1 |
Hamed, MIA | 1 |
Ismail, MI | 1 |
B Elkaeed, E | 1 |
S Abulkhair, H | 1 |
Khattab, M | 1 |
Al-Karmalawy, AA | 1 |
Other Studies
1 other study available for sulfinpyrazone and Cytokine Release Syndrome
Article | Year |
---|---|
Computational Insights on the Potential of Some NSAIDs for Treating COVID-19: Priority Set and Lead Optimization.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Auranofin; Binding Sites; Computational B | 2021 |